Please assess the completion status of the following clinical trial:

Trial Title: Myfortic® for Minimal Change Nephrotic Syndrome (MCNS): a Randomized Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female 18 - 65 years of age~* First histologic diagnosis of MCNS~* Proteinuria \> 3.5 g/day~* Patients who are willing to give written, informed consent~Exclusion Criteria:~* Presence of secondary causes of MCNS~* History of glomerular disease including MCNS~* eGFR \< 50 ml/min/1.73m2~* Renal histology showing pathologies other than MCNS~* Female of child-bearing age who are unwilling to practice effective contraception~* Patients simultaneously participating in another study or who have participated in another study within the last 30 days of entry into this study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Myfortic plus low-dose steroid (Type: EXPERIMENTAL): Not necessary
- Standard-dose steroid (Type: ACTIVE_COMPARATOR): Not necessary

Based on this trial design, predict the completion outcome and termination type (if applicable).